Elevance Health Inc. closed $174.10 below its 52-week high ($567.26), which the company achieved on September 3rd.

The stock has lagged behind the Dow over the longer term as well. ELV stock has declined 16.7% on a YTD basis and 18.5% over the past 52 weeks compared to DOWI’s 18.8% gains in 2024 and 23.9% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elevance Health (ELV – Research Report) received a Buy rating and a $485.00 price target from Cantor Fitzgerald analyst Sarah James yesterday.

In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Elevance Health (ELV – Research Report), with a price ...

The Dow Jones Industrial Average (DJIA) is slipping today despite investors preparing for the upcoming Federal Reserve meeting. Traders have been waiting for this meeting as it will be a major ...

Shares of Elevance Health Inc. ELV shed 0.61% ... with the S&P 500 Index SPX falling 1.07% to 5,906.94 and Dow Jones Industrial Average DJIA falling 0.97% to 42,573.73. This was the stock's ...